Vaccine Immunology — Potentially the Biggest Game Changer in Asian Healthcare
BioSpectrum Asia|BioSpectrum Asia Dec 2021
There is a common pearl of Indian wisdom that encourages parents to let their children play outside in the sun, rain, gardens and mud. The premise is that it allows children to grow closer to nature and natural elements, but it also helps them build immunity and become tough. In modern science, various medical research has reported the benefits of environmental exposure in early childhood for developing immunity.
Vaccine Immunology — Potentially the Biggest Game Changer in Asian Healthcare

Dr Simon Gallagher, General Manager India (interim), ICMEA, Growth And Emerging Markets Business Unit, Takeda, Singapore

There is a common pearl of Indian wisdom that encourages parents to let their children play outside in the sun, rain, gardens and mud. The premise is that it allows children to grow closer to nature and natural elements, but it also helps them build immunity and become tough. In modern science, various medical research has reported the benefits of environmental exposure in early childhood for developing immunity. Conceptually, natural exposure to certain types of common microbes, germs, and allergens contributes to immune development rather than an excessive hygiene lifestyle.

However, these immunity-building efforts are not enough for the millions of more potent and more infectious new and existing pathogens like Dengue and Zika virus that have till now gone under the radar. Historically, such viruses have caused considerable losses to life and the economy and continue to impact the world order today. The ongoing COVID-19 pandemic is the most definitive example of how a flu-like virus can wreak havoc in the world, and that’s where vaccine immunology comes in. After the two deadly COVID-19 waves, the awareness of adult immunisation has started to develop and as a result, the demand for adult vaccination, even for vaccines such as Hepatitis B soared.

この蚘事は BioSpectrum Asia の BioSpectrum Asia Dec 2021 版に掲茉されおいたす。

7 日間の Magzter GOLD 無料トラむアルを開始しお、䜕千もの厳遞されたプレミアム ストヌリヌ、9,000 以䞊の雑誌や新聞にアクセスしおください。

この蚘事は BioSpectrum Asia の BioSpectrum Asia Dec 2021 版に掲茉されおいたす。

7 日間の Magzter GOLD 無料トラむアルを開始しお、䜕千もの厳遞されたプレミアム ストヌリヌ、9,000 以䞊の雑誌や新聞にアクセスしおください。

BIOSPECTRUM ASIAのその他の蚘事すべお衚瀺
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
BioSpectrum Asia

Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time

US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers
BioSpectrum Asia

Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers

Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor of advanced life science products in India.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine
BioSpectrum Asia

Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine

Eppendorf has announced the launch of a CO2 incubator shaker with integrated 180 °C sterilisation routine.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis
BioSpectrum Asia

Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis

US-based Waters Corporation has introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LCMS) analysis.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Singapore designs novel gene therapy offering hope for epilepsy patients
BioSpectrum Asia

Singapore designs novel gene therapy offering hope for epilepsy patients

Researchers from the Yong Loo Lin School of Medicine, National University of Singapore are working on a therapy that holds potential in treating patients with epilepsy, a neurological disorder defined by recurring seizures due to abnormal brain activity.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Spider venom heart drug moves to clinical trials in Australia
BioSpectrum Asia

Spider venom heart drug moves to clinical trials in Australia

A University of Queensland (UQ)-led project in Australia to develop the first-ever drug to treat heart attack and protect donor hearts will move to human clinical trials, after receiving $17.8 million in funding from the Medical Research Future Fund (MRFF).

time-read
1 min  |
BioSpectrum Asia Nov 2024
India develops portable ultrasound scanner for sports injury diagnosis
BioSpectrum Asia

India develops portable ultrasound scanner for sports injury diagnosis

A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-CareUltrasound (POCUS) Scanner for sports injury diagnosis and management.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Integris appoints medtech veteran Probir Das as new CEO
BioSpectrum Asia

Integris appoints medtech veteran Probir Das as new CEO

Integris Healthcare, a global diversified medical technology company, has announced the appointment of Probir Das as Chief Executive Officer (CEO). He will join effective November 2024 and will be based in New Delhi.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Clarity Pharma promotes Michelle Parker to CEO
BioSpectrum Asia

Clarity Pharma promotes Michelle Parker to CEO

Australia-based Clarity Pharmaceuticals has announced the appointment of Michelle Parker as Chief Executive Officer (CEO), effective from October 11, 2024.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Dr Makoto Sugita steps in as President of Nxera Pharma Japan
BioSpectrum Asia

Dr Makoto Sugita steps in as President of Nxera Pharma Japan

Nxera Pharma Co., formerly known as Sosei Group or Sosei Heptares, has announced the appointment of Dr Makoto Sugita, as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer (CMO) of Nxera Pharma.

time-read
1 min  |
BioSpectrum Asia Nov 2024